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Abstract. 
 
Autophagy and the Cvt pathway are examples
of nonclassical vesicular transport from the cytoplasm to
the vacuole via double-membrane vesicles. Apg8/Aut7,
which plays an important role in the formation of such
vesicles, tends to bind to membranes in spite of its hydro-
philic nature. We show here that the nature of the associ-
ation of Apg8 with membranes changes depending on a
series of modiﬁcations of the protein itself. First, the car-
boxy-terminal Arg residue of newly synthesized Apg8 is
removed by Apg4/Aut2, a novel cysteine protease, and a
Gly residue becomes the carboxy-terminal residue of the
protein that is now designated Apg8FG. Subsequently,
Apg8FG forms a conjugate with an unidentiﬁed mole-
cule “X” and thereby binds tightly to membranes. This
modiﬁcation requires the carboxy-terminal Gly residue
of Apg8FG and Apg7, a ubiquitin E1-like enzyme. Fi-
nally, the adduct Apg8FG-X is reversed to soluble or
loosely membrane-bound Apg8FG by cleavage by Apg4.
The mode of action of Apg4, which cleaves both newly
synthesized Apg8 and modiﬁed Apg8FG, resembles that
of deubiquitinating enzymes. A reaction similar to ubiq-
uitination is probably involved in the second modiﬁca-
tion. The reversible modiﬁcation of Apg8 appears to be
coupled to the membrane dynamics of autophagy and
the Cvt pathway.
Key words: autophagy/Cvt pathway • Apg4/Aut2 •
cysteine protease • ubiquitination • deubiquitination
 
Introduction
 
Autophagy is a major pathway for the bulk degradation of
intracellular proteins in a lytic compartment, the lyso-
some/vacuole, and is conserved throughout eukaryotes
 
(Kopitz et al., 1990; Dunn, 1994). In the yeast 
 
Saccharomy-
ces cerevisiae
 
, autophagy is induced when cells are starved
of various nutrients and also upon inhibition of Tor-medi-
ated signaling (Takeshige et al., 1992; Noda and Ohsumi,
1998). During autophagy, cytoplasmic components and or-
ganelles are sequestered in vacuoles by a nonclassical ve-
sicular transport system (Baba et al., 1994). First, autopha-
gosomes, double-membrane structures that surround part
of the cytoplasm, are formed in the cytoplasm next to the
vacuole. Then, the outer membrane of the autophagosome
fuses with the vacuolar membrane and an autophagic
body, consisting of the inner-membrane structure, is re-
leased into the lumen of the vacuole. Finally, the autopha-
gic body is degraded by vacuolar hydrolases (Takeshige et
al., 1992). In 
 
Saccharomyces cerevisiae
 
, the cytoplasm to
vacuole targeting (Cvt)
 
1
 
 pathway is another nonclassical
vesicular transport that delivers aminopeptidase I (API)
from the cytosol to the vacuole (Harding et al., 1995; Baba
et al., 1997; Scott et al., 1997). API is synthesized in the cy-
toplasm as a precursor, proAPI. The precursor is seques-
tered in a small double-membrane vesicle (Cvt vesicle) af-
ter its homooligomerization (Baba et al., 1997; Kim et al.,
1997). The Cvt vesicle fuses with the vacuole, with the sub-
sequent release into the vacuolar lumen of a single mem-
brane structure (Cvt body) that contains proAPI. The en-
tire membrane transport process of the Cvt pathway is
topologically identical to autophagy (Baba et al., 1997;
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Scott et al., 1997) and both pathways share components
that are encoded by the 
 
APG/AUT/CVT 
 
genes (Harding
et al., 1996; Scott et al., 1996). The transport process in
both pathways consists of two major steps; namely, forma-
tion of autophagosome or the Cvt vesicle and fusion of the
vesicle to the vacuole. The targeting and fusion machinery
that functions in the classical vesicular transport pathway
also plays a role in the second step of autophagy and the
Cvt pathway (Darsow et al., 1997; Sato et al., 1998; Fischer
von Mollard and Stevens, 1999; Kim et al., 1999a; Kirisako
et al., 1999). By contrast, details at the molecular level of
the way in which the autophagosome and the Cvt vesicle
are formed remain unclear, although it has been reported
that Tlg2 (t-SNARE) and Vps45 (a homologue of Sec1)
are required only for the first major step in the Cvt path-
way (Abeliovich et al., 1999).
The yeast 
 
apg
 
 mutants have defects in autophagy
(Tsukada and Ohsumi, 1993). The product of the 
 
APG8/
AUT7
 
 gene is a hydrophilic protein (117 amino acids) that
is required for the formation of autophagosomes and Cvt
vesicles (Kirisako et al., 1999; Huang et al., 2000). The
transcription of 
 
APG8
 
 is stimulated in response to nutri-
ent starvation and inhibition of Tor-mediated signaling;
namely, in response to the conditions that induce autoph-
agy (Noda and Ohsumi, 1998; Kirisako et al., 1999). The
intracellular localization of Apg8 changes dramatically af-
ter the shift to starvation conditions. Some Apg8 is con-
centrated selectively in autophagosomes and is trans-
ported to vacuoles with autophagic bodies. In spite of its
hydrophilic nature, considerable amounts of Apg8 are
bound to membrane under both growing and starvation
conditions. Under starvation conditions, more Apg8 is lo-
calized on the membranes of autophagosome intermedi-
ates than on the membranes of mature autophagosomes or
autophagic bodies. This localization suggests that Apg8
might function directly in the assembly of source mem-
branes into the membranes of autophagosomes and, prob-
ably, Cvt vesicles (Kirisako et al., 1999).
A ubiquitination-like system appears to be essential for
both autophagy and the Cvt pathway (Mizushima et al.,
1998). Apg12, a modifier with no apparent similarity to
ubiquitin, is conjugated to Apg5 via an isopeptide bond be-
tween the carboxy-terminal Gly residue of Apg12 and
Lys149 of Apg5. This conjugation reaction requires two
other factors that are essential for autophagy, Apg7 and
Apg10, which function as the E1 and E2 enzymes for
Apg12, respectively (Kim et al., 1999a; Shintani et al., 1999;
Tanida et al., 1999). Since the discovery of ubiquitination
(Hochstrasser, 1996; Varshavsky, 1997; Ciechanover, 1998;
Hershko and Ciechanover, 1998), similar covalent modifi-
cations have been discovered in the various ubiquitin-
related molecules, such as SUMO-1/Smt3 (Matunis et al.,
1996; Johnson et al., 1997; Mahajan et al., 1997), NEDD-8/
Rub1 (Lammer et al., 1998; Liakopoulos et al., 1998; Os-
aka et al., 1998), UCRP (Loeb and Haas, 1992), and Urm1
(Furukawa et al., 2000). Such discoveries suggest that this
type of conjugation system serves as a regulatory mecha-
nism in a variety of cellular processes. Ubiquitin and re-
lated modifiers, with the exception of Apg12 and Urm1,
are synthesized as proproteins, and post-translational pro-
cessing yields the active carboxyl terminus (Kamitani et al.,
1997; Johnson et al., 1997; Ciechanover, 1998; Potter et al.,
1999). Some of the proteases that are responsible for the
 
processing of the proproteins are also able to reverse the
conjugation to liberate the modifiers from the respective
adducts (Wilkinson, 1997; Li and Hochstrasser, 1999; Su-
zuki et al., 1999). Such deconjugation reactions are also in-
volved in numerous biological processes (Huang et al.,
1995; Hegde et al., 1997; Wilkinson, 1997; Desterro et al.,
1998; Li and Hochstrasser, 1999).
Lang et al. (1998) demonstrated that Aut7/Apg8 binds to
Aut2/Apg4, another component that is essential for autoph-
agy and the Cvt pathway. In this study, we clarified the rela-
tionship between Apg8 and Aut2/Apg4, demonstrating that
Apg4 is a novel cysteine protease that cleaves newly syn-
thesized Apg8. We also showed that the cleaved Apg8
(Apg8FG) undergoes reversible modification via reactions
that resemble ubiquitination and deubiquitination, which ap-
pear to be essential for both autophagy and the Cvt pathway.
 
Materials and Methods
 
Yeast Strains, Media, and Construction of Plasmids
 
The yeast strains used in this study are listed in Table I. The media used in
this study were described previously (Kirisako et al., 1999): YPD and
SD
 
1
 
CA media were used for cell growth and SD(-N) medium was used
for nitrogen starvation.
A BamHI site was inserted by PCR in the open reading frame (ORF)
of the 
 
APG8
 
 gene just after the initiation codon or just before the termi-
nation codon, as described previously (Kirisako et al., 1999), and a
BamHI–BamHI fragment containing a 3
 
3
 
 myc sequence was inserted at
each BamHI site. Each 
 
APG8
 
 fragment containing the promoter region
and the inserted 3
 
3
 
 myc sequence was cloned into a yeast centromeric
vector, pRS316 (Sikorski and Hieter, 1989). Using the APG8 plasmid
that encoded Apg8 connected with 3
 
3
 
 myc at the carboxyl terminus, we
generated APG8 plasmids that encoded Apg8-myc variants with muta-
tions in the carboxyl terminal region of Apg8 using QuikChange™, as
described in manufacturer’s protocol (Stratagene). We used oligonu-
cleotides 5
 
9
 
-GGAGAAAATACATTTAAGGGATCCTCTAG-3
 
9
 
, 5
 
9
 
-
GAGAAAATACATTTGGCATGGGATCCTCTAGAGGTG-3
 
9
 
, and
5
 
9
 
-GGAGAAAATACATTTGCCAGGGGATCCTCTAGAGGTG-3
 
9
 
for generation of the plasmids that encoded Apg8FR-myc, Apg8FGM-
myc, and Apg8FAR-myc, respectively. For construction of the APG8
plasmids that encoded Apg8 variants with sequential truncation of indi-
vidual amino acids from the carboxyl terminus and Apg8FA, we gener-
ated the fragments of the 
 
APG8
 
 ORF with mutations in the 3
 
9
 
-terminal
region by PCR using the forward primer 5
 
9
 
-GGAATTCATGAAGTC-
TACATTTAAGTC-3
 
9
 
 and the following reverse primers that included
a BamHI site: 5
 
9
 
-CGGGATCCTTAGCCAAATGTATTTTCTCCT-3
 
9
 
(for Apg8FG), 5
 
9
 
-CGGGATCCTTAAAATGTATTTTCTCCTGAGT-
3
 
9
 
 (for Apg8F), and 5
 
9
 
-CGGGATCCTTAGGCAAATGTATTTTCT-
CCT-3
 
9
 
 (for Apg8FA). The fragments were digested by AccI and BamHI
and substituted for the original AccI–BamHI sequence of the ORF of
 
APG8
 
 in which a BamHI site had been inserted just before the termina-
tion codon. The mutated ORFs of 
 
APG8
 
, connected with the original au-
thentic promoter of the 
 
APG8
 
 gene, were cloned into pRS316.
The 
 
APG4 
 
gene was cloned as reported previously (Kametaka et al.,
1996). To construct the APG4 plasmids, we cloned the BglII–EcoRI frag-
ment that included the ORF of 
 
APG4
 
 into pRS314, pRS316, pRS424, and
pRS426 (Sikorski and Hieter, 1989). Using these plasmids, we generated
plasmids that encoded variants of Apg4 using QuikChange™ with the oli-
gonucleotides 5
 
9
 
-GATATTGGGTGGGGGTCTATGATAAGGACAG-
GAC-3
 
9
 
 (Apg4C159S) and 5
 
9
 
-CTGATATTGGGTGGGGGGCTATGA-
TAAGGACAGGAC-3
 
9
 
 (Apg4C159A).
 
Preparation of Proteins and Apg4-specific Antibodies
 
To prepare glutathione-S-transferase (GST)-fused Apg4 and GST–fused
Apg8-myc, we cloned the ORF of 
 
APG4
 
 and the ORF of 
 
APG8
 
 tagged
with a 3
 
3
 
 myc sequence at the 3
 
9
 
-terminus into pGEX4T and pGEX2T
(Amersham Pharmacia Biotech), respectively. Each plasmid was intro-
duced into 
 
Escherichia coli
 
, XL1-blue. For preparation of GST-Apg4,
transformants in LB medium were stimulated to produce GST-Apg4 by
incubation with 0.1 mM IPTG at 30
 
8
 
C for 3 h. For preparation of GST- 
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Apg8-myc, transformants were incubated in LB medium with 0.5 mM
IPTG at 30
 
8
 
C for 5 h. Cells were lysed by sonication, and then lysates were
centrifuged at 15,000 
 
g
 
 for 15 min. Recombinant proteins recovered in su-
pernatant were allowed to bind to glutathione Sepharose 4B (Amersham
Pharmacia Biotech) and eluted with 20 mM reduced glutathione (Kohjin).
Fractions containing purified GST-Apg4 or GST-Apg8-myc were dialyzed
overnight in a 1,000-fold volume of the reaction buffer described below.
GST-Apg4 was used to immunize a rabbit, and Apg4-specific antibodies
(antiserum) were obtained.
 
Assay of Alkaline Phosphatase Activity
 
Strains with SEY6210 background for assays of alkaline phosphatase
(ALP) activity were obtained as reported previously (Noda et al., 1995).
Preparation of cell lysates and measurement of ALP activity were also
performed as described previously (Noda and Ohsumi, 1998; Kirisako et
al., 1999). Cell lysates for assays were prepared from exponentially grow-
ing cells cultured in SD
 
1
 
CA medium and from cells that had been starved
for 4.5 h in SD(-N) medium.
 
Subcellular Fractionation
 
Cells at the logarithmic phase of growth in YPD medium were converted
to spheroplasts and lysed in lysis buffer (0.2 M sorbitol, 50 mM Tris-HCl,
pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, and Protease Inhibitor
Cocktail™ (Boehringer). Lysates were generated by centrifugation of
crude lysates at 500 
 
g
 
 for 5 min. Low-speed pellet peroxisomes (LSP;
13,000 
 
g
 
 pellet), high-speed pellet peroxisomes (HSP; 100,000 
 
g
 
 pellet),
and high speed supernatants (HSS; 100,000 
 
g
 
 sup) were generated as de-
scribed previously (Kirisako et al., 1999). We examined the distribution of
Apg8 by immunoblotting with a 5,000-fold dilutes of the antibodies
against Apg8 (Kirisako et al., 1999). Signals were detected as reported
previously (Kirisako et al., 1999).
 
Solubilization of Apg8 from Pellet
 
Lysates were prepared as described above. They were centrifuged at 100,000 
 
g
 
for 1 h to generate a pellet without the centrifugation at 13,000 
 
g
 
. The pellet
was suspended in the lysis buffer supplemented with 1 M NaCl or 1% deoxy-
 
cholate. The LSP and HSP prepared from wild-type cells or 
 
D
 
apg4
 
D
 
apg8
 
cells that expressed Apg8FG were treated with 1 M NaCl in the lysis buffer.
The LSP prepared from 
 
D
 
apg4
 
D
 
apg8
 
 cells that expressed Apg8FG was also
suspended in the lysis buffer supplemented with 2 M urea, 0.1 M Na
 
2
 
CO
 
3
 
,
pH 11.5, 1% deoxycholate, or 2% Triton X-100. Suspensions were kept on
ice for 30 min, and then centrifuged at 100,000 
 
g
 
 for 1 h to generate superna-
tants and pellets. Proteins in each fraction were precipitated with 10% TCA
and resuspended in a sample buffer for SDS-PAGE. The distribution of
Apg8 was examined by immunoblotting as described above.
 
Assay of Cleavage of Apg8 In Vitro
 
Growing cells were harvested and lysed in reaction buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl) with glass beads, as described previously (Kir-
isako et al., 1999). Lysates were prepared from 
 
D
 
apg8
 
, 
 
D
 
apg4
 
D
 
apg8,
 
 and
 
D
 
apg4
 
D
 
apg
 
8 cells that expressed Apg8-myc and the concentration of pro-
tein in the lysates was adjusted to 6, 6, and 3 mg/ml, respectively. Lysates
were incubated at 30
 
8
 
C for 10 min, and then the lysate that contained
Apg8-myc was mixed with the lysate of 
 
D
 
apg8
 
 or 
 
D
 
apg4
 
D
 
apg8
 
 cells at a vol-
ume ratio of 1:2. Then the mixtures were incubated at 30
 
8
 
C for various pe-
riods of time. For assays of the effects of protease inhibitors, the lysate con-
taining Apg8-myc was incubated with the lysate of 
 
D
 
apg8 
 
cells (which
expressed Apg4) at 30
 
8
 
C for 1 h in the presence of 1 mM 
 
N
 
-ethylmaleimide
(NEM), 1 mM PMSF, 1 mM pepstatin, or 10 mM 1,10-phenanthroline. For
cleavage assay of recombinant Apg8 by recombinant Apg4, 300 ng of GST-
Apg8-myc were incubated with 500 ng of GST-Apg4 in 30 
 
m
 
l of reaction
buffer with or without 1 mM DTT at 30
 
8
 
C for 1 h. As a control, 300 ng of
GST-Apg8-myc were incubated similarly with 500 ng of GST. Processing of
Apg8-myc and GST-Apg8-myc was examined by immunoblotting with the
Apg8-specific antibodies and a monoclonal myc-specific antibody, 9E10.
The LSP and HSP of 
 
D
 
apg4
 
D
 
apg8
 
 cells that expressed Apg8FG and the
HSS of 
 
D
 
apg4
 
D
 
apg8
 
 and 
 
D
 
apg4
 
D
 
apg8
 
 cells that expressed Apg4 or
Apg4C159S from pRS426-based multicopy plasmid were prepared as de-
scribed above. The LSP and HSP were washed once with lysis buffer and
resuspended in 50 mM Tris-HCl, pH 7.5, at 3 and 6 mg protein/ml, respec-
tively. The concentration of protein in each HSS was adjusted to 10 mg
protein/ml in 50 mM Tris-HCl, pH 7.5. The suspension of the LSP was in-
cubated with an equal volume of HSS at 30
 
8
 
C for 1 h, with subsequent cen-
trifugation at 100,000 
 
g
 
 for 1 h to generate a supernatant and a pellet. The
 
Table I. Strains Used in this Study
 
Strain Genotype Source
 
SEY6210
 
MAT
 
a
 
 leu2 ura3 his3 trp1 lys2 suc2-
 
D
 
9
 
Darsow et al., 1997
KVY5
 
MAT
 
a
 
 leu2 ura3 his3 trp1 lys2 suc2-
 
D
 
9 
 
D
 
apg8::HIS3
 
Kirisako et al., 1999
KVY13
 
MAT
 
a
 
 leu2 ura3 his3 trp1 lys2 suc2-
 
D
 
9 
 
D
 
apg4::LEU2
 
This study
KVY15
 
MAT
 
a
 
 leu2 ura3 his3 trp1 lys2 suc2-
 
D
 
9 
 
D
 
apg8::HIS3 
 
D
 
apg4::LEU2
 
This study
KVY52
 
MAT
 
a
 
 leu2 ura3 his3 trp1 lys2 suc2-
 
D
 
9 
 
D
 
apg8::HIS3 
 
D
 
apg4::LEU2 
 
D
 
pho8::PHO8
 
D
 
60
 
This study
KVY53
 
MAT
 
a
 
 leu2 ura3 his3 trp1 lys2 suc2-
 
D
 
9 
 
D
 
apg4::LEU2 
 
Dpho8::PHO8D60 This study
KVY54 MATa leu2 ura3 his3 trp1 lys2 suc2-D9 Dapg8::HIS3 Dpho8::PHO8D60 This study
KVY118 MATa leu2 ura3 his3 trp1 lys2 suc2-D9 Dapg7::HIS3 This study
KVY135 MATa leu2 ura3 his3 trp1 lys2 suc2-D9 Dapg6::LEU2 This study
NNY20 MATa leu2 ura3 trp1 Dapg1::LEU2 Matsuura et al., 1997
MT2-4-3 MATa ura3 apg2 Lab stock
TKD3 MATa leu2 ura3 trp1 Dapg3::LEU2 Lab stock
TID4-2D MATa leu2 ura3 trp1 Dapg4::LEU2 Lab stock
SKD5-1D MATa leu2 ura3 trp1 Dapg5::LEU2 Kametaka et al., 1996
SKD6-1d MATa leu2 ura3 trp1 Dapg6::LEU2 Kametaka et al., 1998
TID7-1 MATa leu2 ura3 trp1 Dapg7::LEU2 Lab stock
CTD1 MATa leu2 ura3 trp1 Dapg9::TRP1 Noda et al., 2000
TFD10-L1 MATa leu2 ura3 trp1 Dapg10::LEU2 Shintani et al., 1999
NMY101 MATa leu2 ura3 trp1 his3 Dapg12::HIS3 Mizushima et al., 1998
TFD13-W3 MATa leu2 ura3 trp1 Dapg13::TRP1 Funakoshi et al., 1997
SKD14-1C MATa leu2 ura3 trp1 Dapg14::LEU2 Kametaka et al., 1998
MT15-4-3 MATa leu2 ura3 apg15 Lab stock
NMY124 MATa leu2 ura3 trp1 his3 Dapg16::HIS3 Mizushima et al., 1998The Journal of Cell Biology, Volume 151, 2000 266
suspensions of the LSP and HSP were incubated with an equal volume of
HSS containing Apg4, or not, with subsequent treatment with/without 1 M
NaCl, and then separated to supernatants and pellets by the same way.
The distribution of Apg8 was examined by immunoblotting as described
above. The LSP was also incubated with 500 ng of recombinant GST-Apg4
or GST in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 1 mM DTT, with
subsequent centrifugation at 100,000 g for 1 h. The resulting supernatant
was subjected to immunoblotting with the Apg8-specific antibodies.
Mass Spectrometry
Protein samples were prepared from GST-Apg8-myc by incubation with
thrombin and subsequent treatment with GST-Apg4. Matrix-assisted laser
desorption ionization (MALDI)–mass spectrometry (MS) was performed
using a Voyager Elite XL time-of-flight mass spectrometer. Protein sam-
ples were mixed with the matrix solution, the supernatant of a 50% aceto-
nitrile solution saturated with a-cyano-4-hydroxycinnamic acid, and then
air dried on the flat surface of a stainless steel plate. Ions were generated
by irradiating the sample area with the output of a nitrogen laser at a
wavelength of 337 nm.
Results
Cleavage of Newly Synthesized Apg8
Requires Apg4/Aut2
During our efforts to characterize Apg8, we constructed
apg8 null mutants that expressed two versions of Apg8
tagged with three consecutive myc epitopes at the car-
boxyl or amino terminus; namely, Apg8-myc and myc-
Apg8, respectively. Each tagged Apg8 restored the au-
tophagic activity of the apg8 null mutants (data not
shown). We attempted to detect the products of the gene
constructs by immunoblotting with Apg8-specific antibod-
ies and a monoclonal myc-specific antibody, 9E10. Lysates
were prepared by breaking with glass beads, as described
previously (Kirisako et al., 1999). In cells that expressed
myc-Apg8, we detected the myc-tagged form of Apg8 with
both types of antibody (Fig. 1 A, 3 and 5). No signal was
detected with the myc-specific antibody in cells that ex-
pressed Apg8-myc (Fig. 1 A, 6). In the cells that expressed
Apg8-myc, the Apg8-specific antibodies generated a band
at the same position as endogenous Apg8 and not at the
expected position (Fig. 1 A, 4). These results indicated
that newly synthesized Apg8 had been cleaved in its car-
boxy-terminal region in vivo.
Using apg mutants that expressed Apg8-myc, we exam-
ined whether other Apg proteins might be required for the
cleavage of newly synthesized Apg8. Only in apg4 null mu-
tant, Apg8-myc remained unprocessed, while the myc
epitopes were completely removed in the other mutants
(Fig. 1 B). The APG4 gene has been shown to be allelic to
the AUT2 gene (Lang et al., 1998; Kirisako et al., 1999).
Therefore, we concluded that Apg4/Aut2 is required for
the cleavage that occurs near the carboxyl terminus of
newly synthesized Apg8.
Apg4 Is a Novel Cysteine Protease
A lysate of yeast cells containing Apg8-myc but not Apg4
was mixed with a lysate that contained Apg4 but not Apg8,
and the mixture was incubated at 308C for the indicated
times (Fig. 2 A). The level of the processed form of Apg8
increased in a time-dependent manner, with a parallel de-
crease in the level of Apg8-myc. No cleavage was detected
in the absence of Apg4 (Fig. 2 A). Thus, the cleavage of
Apg8 in vitro also depended on Apg4. We performed the
same experiment in the presence of representative inhibi-
tors of cysteine, serine, aspartic, and metallo-proteases
(NEM, PMSF, pepstatin, and 1,10-phenanthroline, respec-
tively). As shown in Fig. 2 B, cleavage was only inhibited in
the presence of NEM, suggesting that cleavage of Apg8
was catalyzed by a cysteine protease. This cleavage pro-
ceeded even in the presence of the 33 myc sequence at the
carboxyl terminus of Apg8. Thus, it is likely that the rele-
vant protease has endopeptidase activity.
We next investigated the possibility that Apg4 itself
might catalyze the processing of Apg8. GST-fused forms of
Apg4 and Apg8-myc (GST-Apg4 and GST-Apg8-myc)
were expressed in E. coli and purified on a column of glu-
tathione-Sepharose. Then we incubated GST-Apg8-myc
with GST-Apg4 at 308C for 1 h in 50 mM Tris-HCl, pH 7.5,
150 mM NaCl, and 1 mM DTT. Subsequent immunoblot-
ting with the Apg8-specific antibodies revealed two bands
with different mobilities (Fig. 2 C, left). The rapidly mi-
grating band was not detected with the myc-specific anti-
body (data not shown). In addition, after the incubation of
GST-Apg8-myc with GST, only the slowly migrating band
was detected with the Apg8-specific antibodies (Fig. 2 C,
right). These data provided strong evidence that GST-
Apg4 cleaved GST-Apg8-myc directly in the carboxy-ter-
minal region of Apg8. The reaction barely proceeded in
the absence of a reducing reagent (DTT; Fig. 2 C, middle).
Taken together, the results indicate that Apg4 is a novel
cysteine endopeptidase that cleaves Apg8 in its carboxy-
terminal region.
Figure 1. Processing of Apg8. (A) Removal of myc epitopes con-
nected to the carboxyl terminus of Apg8. Lysates were prepared
from logarithmically growing cultures of wild-type cells (SEY6210;
1), Dapg8 cells (KVY5; 2), and Dapg8 cells that expressed myc-
Apg8 (3 and 5) or Apg8-myc (4 and 6) encoded by a centromeric
plasmid. Lysates were subjected to immunoblotting with Apg8-
specific antibodies (a-Apg8; 1–4) or a monoclonal antibody against
myc, 9E10 (a-myc; 5 and 6). (B) Cleavage of Apg8-myc in apg mu-
tant cells. The centromeric plasmid encoding Apg8-myc was intro-
duced into the various lines of apg mutant cells. Lysates were pre-
pared and subjected to immunoblotting as described above. Lane
numbers correspond to the designations of the apg mutants. Note
that endogenous Apg8 was expressed in these mutants.Kirisako et al. Reversible Modification of Apg8/Aut7 267
Cys159 of Apg4 Is Essential for Protolytic Activity
We performed BLAST searches to identify proteins ho-
mologous to Apg4 in higher eukaryotes and found several
proteins that have not yet been characterized (Fig. 3 A).
After aligning the amino acid sequences of Apg4 and these
homologues, we identified several conserved regions in the
primary structures of the proteins. In the most strongly
conserved region, we recognized only a single invariant
cysteine residue (corresponding to Cys159 of Apg4) (Fig. 3
A, arrow), which could be involved in formation of a cata-
lytic active site. We then replaced Cys159 of Apg4 with Ser
(Apg4C159S) or Ala (Apg4C159A) by site-directed mu-
tagenesis. These variants of Apg4 were expressed in Dapg4
cells that produced Apg8-myc and cleavage of Apg8-myc
was examined. Cleavage of Apg8-myc was detected in cells
that expressed wild-type Apg4, but not in cells that ex-
pressed the variants (Fig. 3 B). Both variants were ex-
pressed from multicopy plasmids and were stable (Fig. 3
B). Thus, the defect in processing was presumably due to
loss of proteolytic activity. We postulated that Cys159 of
Apg4 is a catalytically active amino acid.
The Cvt pathway can be monitored by following the
maturation of proAPI. We investigated the maturation of
proAPI in Dapg4 cells that expressed wild-type Apg4 or
the variants by immunoblotting with API-specific antibod-
ies (a gift from Dr. D.J. Klionsky, University of California
at Davis, Davis, CA). As shown in Fig. 3 B, proAPI did
not undergo maturational processing in cells that ex-
pressed the protease-negative variants of Apg4. We also
examined the effects of these variants on autophagy using
the ALP assay system that was developed by Noda et al.
(1995) to measure autophagic activity. The autophagic
activity in Dapg4 cells that expressed Apg4C159S or
Apg4C159A was reduced to the level of that in the apg4
null mutant cells (Fig. 3 C). These results clearly demon-
strated that the proteolytic activity of Apg4 was necessary
both for autophagy and for the Cvt pathway.
Apg8 Exposes Gly at the Carboxyl Terminus by Apg4
Apg8-myc variants with a mutation in the carboxy-termi-
nal region of Apg8 (Fig. 4 A) were expressed in Dapg8
cells. Hereafter, to facilitate identification of the various
forms of Apg8, the carboxy-terminal sequence of Apg8 is
written after Apg8. Thus, the wild-type newly synthesized
Apg8 is written as Apg8FGR. Apg8FGM-myc, in which
the carboxy-terminal Arg residue of Apg8 had been re-
placed with a Met residue, was cleaved as effectively as
Apg8FGR-myc (Fig. 4 B, 1 and 2). However, when the
second residue (Gly116) from the carboxyl terminus of
Apg8 was deleted (Apg8FR-myc), no cleavage occurred
(Fig. 4 B, 3). The replacement of Gly116 by Ala
(Apg8FAR) also resulted in loss of cleavage (Fig. 4 B, 4).
These results demonstrated that Gly116 was essential for
the cleavage of Apg8 by Apg4. Since Apg4 cleaved
Apg8FGM-myc in the normal manner (Fig. 4 B, 2), it ap-
pears that Apg4 recognizes the upstream region beyond
Gly116 of Apg8FGR irrespective of the presence or ab-
sence of the carboxy-terminal Arg. This hypothesis is sup-
ported by the fact that Apg8 and its homologues have
strong similarity in their upstream sequences from the
conserved Gly residue, which corresponds to Gly116 of
Apg8 (Fig. 4 C, arrowhead), whereas they have variable
sequences in the downstream region.
The homology shown in Fig. 4 C also prompted us that
Apg4 might cleaved just after Gly116 of Apg8. In addi-
tion, Meyers et al. (1998) reported that a polyprotein that
included part of the sequence of LC3, a mammalian ho-
mologue of Apg8, was cleaved by a cellular protease af-
ter Gly120, which is corresponding to the invariant Gly
residue in Apg8 and its homologues (Fig. 4 C, arrow-
head). To determine the cleavage site of Apg8, we exam-
ined Apg8 generated by cleavage by Apg4 using mass
spectrometry. GST-Apg8-myc was treated first with
thrombin to remove GST, and then with GST-Apg4.
MALDI-TOFMS gave a signal at 13,864.0 (Fig. 4 D, ar-
rowhead). This value was well assigned to the predicted
mass (13,864.0) of Apg8 terminating in Gly116 (the first
Met was replaced with Gly-Ser-Pro-Gly-Ile-Leu). Thus,
we confirmed that Apg8 was cleaved just after Gly116 by
Apg4 and exposed the Gly at the COOH terminus.
Figure 2. Cleavage of Apg8 by Apg4 in vitro. (A) Cleavage of
Apg8-myc by Apg4 in vitro. Lysates were prepared from vegeta-
tive cultures of Dapg8 cells (KVY5), Dapg4Dapg8 cells (KVY15),
and Dapg4Dapg8 cells that expressed Apg8-myc encoded by a
centromeric plasmid as described in Materials and Methods. A ly-
sate of Dapg4Dapg8 cells that expressed Apg8-myc was incubated
with a lysate of Dapg8 or Dapg4Dapg8 cells at 308C for the indi-
cated times, and then subjected to immunoblotting with Apg8-
specific antibodies. (B) Effects of protease inhibitors on cleavage
of Apg8-myc. A lysate of Dapg4Dapg8 cells that expressed Apg8-
myc was incubated with a lysate of Dapg8 cells at 308C for 1 h in
the presence of various protease inhibitors, as follows, with the
type of protease indicated in parentheses: 1 mM NEM (cysteine;
2), 1 mM PMSF (serine; 3), 1 mM pepstatin (aspartic; 4), and 10
mM 1,10-phenanthroline (metallo-; 5). The result of the reaction
in the absence of inhibitors is shown in 1. Cleavage of Apg8-myc
was examined by immunoblotting with Apg8-specific antibodies.
(C) Cleavage of recombinant Apg8-myc by recombinant Apg4.
GST-Apg8-myc, GST-Apg4, and GST were prepared as de-
scribed in Materials and Methods. GST-Apg8-myc was incubated
with GST-Apg4 in the presence of 1 mM DTT (1) or in its ab-
sence (2) at 308C for 1 h. As a control, GST-Apg8-myc was
treated with GST in the presence of 1 mM DTT at 308C for 1 h.
Cleavage of GST-Apg8-myc was examined as described above.The Journal of Cell Biology, Volume 151, 2000 268
Figure 3. Identification of Apg4 as a novel cysteine protease. (A) Alignment of the amino acid sequences of Apg4 and its homologues
from other organisms. An arrowhead indicates the most likely candidate for the cysteine residue at the active site of these enzymes. The
homologues include two proteins from Homo sapiens (HsApg4A; deduced amino acid sequence based on an EST clone with GenBank
No. W30741 and a genomic sequence from 889N15 with No. AL031177, and HsApg4B, No. AL080168), two proteins from Caenorhab-
ditis elegans (CeApg4A and CeApg4B; Nos. Z68302 and AL110500) and one protein from Arabidopsis thaliana (AtApg4; No.
AC004005). (B) Effects of the replacement of Cys159 of Apg4 on the cleavage of Apg8 and the Cvt pathway. (Top) Cleavage of Apg8-
myc. Wild type of Apg4 (W.T.; 1), Apg4C159S (2), and Apg4C159A (3) were expressed from centromeric plasmids derived from
pRS314 in Dapg4Dapg8 cells (KVY15) that expressed Apg8-myc encoded by a centromeric plasmid. Lysates were prepared from expo-
nentially growing cells and subjected to immunoblotting with Apg8-specific antibodies. (Middle) The Cvt pathway. Apg4, Apg4C159S,
and Apg4C159A encoded by centromeric plasmids were expressed in Dapg4 cells (KVY13). Maturation of proAPI in growing cells was
examined by immunoblotting with API-specific antibodies. (Bottom) Detection of Apg4 and its variants. Apg4 and its variants were ex-
pressed from pRS426-based 2-ml plasmids in Dapg4 cells (KVY13) and detected by immunoblotting with Apg4-specific antibodies. (4)
Dapg4 cells that harbored the vector only. (C) Effects of mutation of Cys159 in Apg4 on autophagy. Apg4, Apg4C159S, and
Apg4C159A were expressed from centromeric plasmids in Dapg4 cells (KVY53) that expressed Pho8D60. Cells at the logarithmic phase
of growth in SD1CA medium were transferred to nitrogen-starvation medium, SD(-N), for 4.5 h. Lysates were prepared from growing
(open bars) and starved (closed bars) cells. ALP activity in each lysate was measured as described previously (Noda and Ohsumi, 1998).
Values shown are means 6 SD of results from triplicates in each case. Numbering of columns corresponds to the numbering of lanes in B.Kirisako et al. Reversible Modification of Apg8/Aut7 269
Carboxy-terminal Glycine of Apg8 Is Necessary for the 
Autophagy/Cvt Pathway
We investigated activities of variants of Apg8 with
changes in the carboxy-terminal amino acid (Fig. 5 A) in
autophagy and the Cvt pathway (Fig. 5, B and D).
Apg8FGR allowed both maturation of proAPI and in-
creased ALP activity in Dapg8 cells only when Apg4 was
present. Apg8FG was also fully active in both pathways in
Dapg8 cells even, to some extent, in the absence of Apg4.
Apg8F did not suppress the defect in autophagy or in the
Cvt pathway in Dapg8 cells irrespective of the presence or
absence of Apg4. Furthermore, the replacement of the
carboxy-terminal Gly of Apg8 (Apg8FA) resulted in the
disruption of both pathways (Fig. 5, C and D). These data
indicated that Apg8FG was functional in both pathways.
The carboxy-terminal Gly residue of Apg8FG appears to
have a crucial role in autophagy and the Cvt pathway.
Apg8FG Is Converted to a Tightly
Membrane-associated Form
We examined the intracellular distribution of Apg8 and its
variants (Fig. 5 A). More than half of each form was recov-
ered in the pellet after centrifugation at 100,000 g for 1 h,
and all pelleted Apg8 was almost completely solubilized
by the detergent, deoxycholate at 1% (Fig. 6 A; DOC).
These results suggested that all forms of Apg8 recovered
in the 100,000 g pellet were associated with membranes.
Next, we treated each pellet with 1 M NaCl (Fig. 6 A). In
wild-type cells, in which most Apg8FGR was converted to
Apg8FG by Apg4 (Fig. 1 A), about half of the Apg8 was
solubilized and the rest remained pelletable (Fig. 6 A;
Apg8FGR, wild type). By contrast, Apg8FGR expressed
in apg4 null mutant cells was completely solubilized by
such treatment (Fig. 6 A; Apg8FGR, Dapg4). The results
demonstrated that Apg8 was converted to an NaCl-insolu-
ble form only after cleavage by Apg4. Furthermore, we
found that neither Apg8F nor Apg8FA was converted to
NaCl-insoluble Apg8 irrespective of the presence or ab-
sence of Apg4 (Fig. 6 A; Apg8F and Apg8FA, Dapg8, and
data not shown). The data indicated that the carboxy-ter-
minal Gly residue of Apg8FG was essential for the conver-
sion. Because the converted form of Apg8FG (referred to
hereafter as Apg8FG*) was solubilized by detergent and
not by 1 M NaCl, Apg8FG* must have been bound tightly
to membranes.
We next fractionated cells by centrifugation to generate
a 13,000 g pellet (LSP), a 100,000 g pellet (HSP), and a
100,000 g supernatant (HSS). By this fractionation, marker
proteins, such as ALP for the vacuole, Kex2p for Golgi ap-
paratus, and alcohol dehydrogenase for the cytosol, were
recovered in the LSP, HSP, and HSS, respectively (a small
amount of Kex2p was detected in the LSP) (data not
shown). In wild-type cells, Apg8 was distributed in all frac-
tions, as reported previously (Fig. 6 A; Apg8FGR, wild
type; Kirisako et al., 1999). By contrast, Apg8FGR
(Dapg4), Apg8F, and Apg8FA were recovered in the HSP
and HSS, but not in the LSP (Fig. 6 A). These results indi-
cated that the appearance of Apg8 in the LSP depended
on the carboxy-terminal Gly and thereby Apg8 in the frac-
tion represented Apg8FG*. In wild-type cells, although
Apg8FG* occupied about half of the whole pelleted Apg8,
only several percent of Apg8 were collected in the LSP
(Fig. 6 A; Apg8FGR, wild type, compare left with right).
This suggested that Apg8FG* might be recovered not only
in the LSP but also HSP. The lysates of wild-type cells
were separated to the LSP and the HSP. Both were
treated with 1 M NaCl, with subsequent centrifugation at
100,000 g for 1 h to generate supernatants and pellets. As
shown in Fig. 6 B, the LSP contained Apg8FG* only,
whereas the HSP contained two forms of Apg8, Apg8FG
and Apg8FG*.
Apg8FG and Apg12 exhibit weak homology in their car-
boxy-terminal regions and both terminate with Phe-Gly
Figure 4. Cleavage of Apg8. (A) Schematic representation of
Apg8-myc fusion proteins. The amino acid sequence of the
Apg8-myc junction is shown in the single-letter code. (B) Cleav-
age of Apg8-myc and its variants. Lysates were prepared from
the logarithmically growing Dapg8 cells (KVY5) that expressed
the fusion proteins depicted in A from pRS316-based plasmids.
Numbering of lanes corresponds to the numbering of the pro-
teins in A. (C) Alignment of the amino acid sequences of car-
boxy-terminal segments of Apg8 and representative homologues.
An arrowhead indicates the Gly residue at the cleavage site of
Apg8 and, possibly, of the homologues. Apg8/Aut7 (S. cerevi-
siae), SpApg8 (Schizosaccharomyces pombe; GenBank No.
AL032684), HsGATE-16/GEF2 (H. sapiens), RnGATE-16/
GEF2 (Rattus norvegicus), RnLC3 (R. norvegicus), AtApg8 (A.
thaliana; No. AC006220), and Lb-Aut7 (Laccaria bicolor; Kim et
al., 1999b). (D) MALDI mass spectra of Apg8 (top) and Apg8-
myc (bottom). Arrowhead, Apg8 generated by cleavage by
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(Ichimura, Y., T. Kirisako, N. Ishihara, N. Mizushima, M.
Ohsumi, T. Noda, and Y. Ohsumi, manuscript in prepara-
tion). Apg12 is covalently attached to Apg5 via the activat-
ing enzyme Apg7 (Mizushima et al., 1998; Kim et al.,
1999a; Tanida et al., 1999). We examined whether Apg7
might similarly be involved in the generation of Apg8FG*
(Fig. 6). In Dapg7 mutant, Apg8 was completely solubi-
lized by the treatment with 1 M NaCl, and none was de-
Figure 5. Autophagy and the
Cvt pathway in the presence of
carboxy-terminal variants of
Apg8. (A) Schematic represen-
tation of the variants of Apg8.
Carboxy-terminal sequences are
shown. (B and C) The Cvt path-
way. (B) Apg8 and its variants
were expressed in Dapg8 cells
(KVY5) and in Dapg4Dapg8
cells from the pRS316 vector.
(C) Apg8FGR and Apg8FA
were expressed in Dapg8 cells
(KVY5) from pRS316-based
centromeric plasmids. Matura-
tion of proAPI in cells at the
logarithmic phase of growth was
examined by immunoblotting
with API-specific antibodies.
Expression of each variant of
Apg8 was detected with Apg8-
specific antibodies. Numbering
of lanes corresponds to the num-
bering of constructs in A. mAPI,
mature API. (D) Autophagy
(ALP assay). Each pRS316-
based plasmid encoding Apg8 or a variant was introduced into mutants with SEY6210 background, namely, Dapg8 (KVY54) and
Dapg4Dapg8 (KVY52), which expressed Pho8D60. Cells were cultured in SD1CA medium to logarithmic phase and transferred to ni-
trogen-starvation medium, SD(-N), for 4.5 h. Lysates were prepared from growing (open bars) and starved (closed bars) cells. ALP ac-
tivity in each lysate was measured as described previously. Values shown are means 6 SD of results from triplicates in each case. Num-
bering of columns corresponds to the numbering of constructs in A. v, cells harboring the vector only. 
Figure 6. Distribution of Apg8.
(A) Lysates were prepared from
SEY6210 cells (Apg8FGR; wild
type), KVY13 cells (Apg8FGR;
Dapg4), KVY5 cells that ex-
pressed Apg8F (Apg8F; Dapg8),
or Apg8FA (Apg8FA; Dapg8),
KVY 135 cells (Apg8FGR;
Dapg6), KVY118 cells
(Apg8FGR;  Dapg7), and KVY15
cells that expressed Apg8FG
(Apg8FG;  Dapg4Dapg8), as de-
scribed in Materials and Meth-
ods. (Left) Solubilization. Lysates
were centrifuged at 100,000 g
for 1 h to generate pellets. The
pellets were treated with 1 M
NaCl or 1% deoxycholate
(DOC) or held untreated (Non)
on ice for 30 min, and then cen-
trifuged at 100,000 g for another
1 h to generate to supernatants
(S) and pellets (P). (Right) Sub-
cellular distribution. Lysates
were centrifuged at 13,000 g for
15 min to generate supernatants
and pellets (LSP). The resulting supernatants were then centrifuged at 100,000 g for 1 h to generate supernatants (HSS) and pellets (HSP).
The distribution of Apg8 was examined by immunoblotting with Apg8-specific antibodies. (B) The LSP and the HSP of wild-type cells
(SEY6210) were treated with 1 M NaCl or held untreated (Non) on ice for 30 min, and then centrifuged 100,000 g for 1 h to generate to su-
pernatants (S) and pellets (P). Apg8 was detected as described above.Kirisako et al. Reversible Modification of Apg8/Aut7 271
tected in the LSP even though Apg4 had completely
cleaved Apg8FGR (Fig. 1 B). In another apg mutant
(Dapg6), the distribution of Apg8 was similar to that in
wild-type cells. These data indicated that the defects in
the generation and recovery in the LSP of Apg8FG*
were caused directly by the lack of Apg7. Thus, Apg7 ap-
peared to be necessary for the conversion of Apg8FG to
Apg8FG* (see Discussion).
Cleavage of Apg8FG* by Apg4 Is Required for the 
Autophagy/Cvt Pathway
The formation of Apg8FG* was apparently essential for
autophagy and the Cvt pathway. Therefore, we expected
that both pathways would proceed normally without Apg4
if Apg8FG was produced. However, as shown in Fig. 5, B
and D, in Dapg4Dapg8 cells that expressed Apg8FG, the
activities of both pathways were reduced but not elimi-
nated. These data suggested that Apg4 was required in an-
other step in addition to the cleavage of newly synthesized
Apg8 (Apg8FGR).
We investigated the distribution of Apg8 in Dapg4Dapg8
cells that expressed Apg8FG. As shown in Fig. 6
(Apg8FG,  Dapg4Dapg8), most of the pelletable Apg8 was
in an NaCl-insoluble form and the amount of Apg8 in the
LSP was drastically increased. The Apg8 that accumulated
in the LSP could not be solubilized by 1 M NaCl (Fig. 7 A,
left), demonstrating that all the Apg8 in the LSP was
present as Apg8FG*. Apg8FG* in the LSP was not solubi-
lized by 2 M urea or 0.1 M Na2CO3 either, but it was done
by the detergents, 1% deoxycholate and 2% Triton X-100.
(Fig. 7 A, left). This result suggested that Apg8FG* had
acquired a feature similar to those of integral membrane
proteins.
A possible hypothesis that explains the accumulation of
Apg8FG* in the absence of Apg4 is that Apg4 maintains
the level of Apg8FG*. To test this hypothesis, we per-
formed in vitro cleavage assay against Apg8FG* using the
LSP that accumulated Apg8FG*. The LSP was incubated
in 50 mM Tris-HCl with HSS fractions from Dapg4Dapg8
cells and from Dapg4Dapg8 cells that expressed Apg4 or
Apg4C159S at 308C for 1 h, with subsequent centrifuga-
tion at 100,000 g for 1 h. As shown in Fig. 7 B, Apg8 was
detected in the resulting supernatant in the presence
of Apg4. No such release was observed in the presence
of 1 mM NEM. A protease-negative form of Apg4
(Apg4C159S) also failed to release Apg8 from the LSP
(Fig. 7 B) and was unable to suppress the partial defects in
autophagy and the Cvt pathway in Dapg4Dapg8 cells that
expressed Apg8FG (data not shown). Furthermore, such
release could be demonstrated with recombinant GST-
Apg4 even in the absence of the yeast cytosol (z5% of in-
putted Apg8 was liberated from the pellet) (Fig. 7 C).
These data indicated that Apg4 acted on Apg8FG* pro-
teolytically.
Apg4 Attacks Apg8FG* both in the LSP and in the HSP 
In Vitro
Unexpectedly, Apg8 was released from the LSP without
1 M NaCl treatment (Fig. 7 B), although Apg8 itself has
an affinity to membranes without the conversion to
Apg8FG* (Fig. 6 A). We examined whether Apg8 re-
mained as an NaCl-soluble form on the LSP treated with
the HSS that contained Apg4. As shown in Fig. 7 D, the
release from the LSP was little increased in the presence
of 1 M NaCl. We found that Apg8FG* was also accumu-
lated in the HSP of Dapg4Dapg8 cells expressing Apg8FG
(Fig. 7 A, right). Therefore, we performed the same exper-
iment on the HSP. The HSP was treated with the HSS of
Dapg4Dapg8 cells that expressed Apg4. After treatment
with 1 M NaCl, or not, the mixture was centrifuged at
100,000  g for 1 h. As shown in Fig. 7 D, Apg8 was little re-
leased from the pellet in the absence of 1 M NaCl, whereas
nearly half of Apg8 was released in the presence of 1 M
NaCl. These data clearly indicated that Apg4 attacked
Apg8FG* both in the HSP and in the LSP in vitro. In addi-
tion, they suggested that Apg8 (not Apg8FG*) should
have different affinities to the membranes in the HSP and
in the LSP. The Apg8FG*-localized membranes in these
two fractions might have different composition.
Figure 7. Cleavage of Apg8FG* by Apg4. Solubilization of the
Apg8 recovered in the LSP. (Left) The LSP was prepared from
the Dapg4Dapg8 cells (KVY15) that expressed Apg8FG, as de-
scribed in Fig. 6. It was treated with 1 M NaCl, 2 M Urea, 0.1 M
Na2CO3, pH 11.5, 1% deoxycholate (DOC), or 2% Triton X-100
(TX100) or held untreated (Non) on ice for 30 min, with subse-
quent centrifugation at 100,000 g for 1 h to generate a superna-
tant (S) and a pellet (P). (Right) The HSP prepared from the
Dapg4Dapg8 cells (KVY15) that expressed Apg8FG was treated
with NaCl or not, and then separated to a supernatant (S) and a
pellet (P). The distributions of Apg8 were examined by immuno-
blotting with Apg8-specific antibodies. (B and C) Release of
Apg8 from the LSP of Dapg4Dapg8 cells (KVY15) expressing
Apg8FG. (B) The LSP was incubated at 308C for 1 h with the
HSS fractions that were prepared from Dapg4 cells (KVY13; 1)
and Dapg4 cells that expressed Apg4 (2 and 3) or Apg4C159S (4)
from a multicopy vector (pRS426). The reaction with the HSS
that contained Apg4 was performed in the presence (3) or ab-
sence (2) of 1 mM NEM. Then, reaction mixtures were centri-
fuged at 100,000 g for 1 h to separate to supernatants (S) and pel-
lets (P). (C) The LSP was incubated with GST-Apg4 or GST at
308C for 1 h, and then the reaction mixtures were centrifuged at
100,000 g for 1 h to generate supernatants. Apg8 was detected by
immunoblotting with Apg8-specific antibodies. I, 5% of input.
(D) Release of Apg8 from the HSP and LSP. The HSP and LSP
were prepared from of Dapg4Dapg8 cells (KVY15) expressing
Apg8FG. Both were first treated with the HSS that was prepared
from Dapg4 cells that expressed Apg4, and then with 1 M NaCl or
held untreated (Non). The mixtures were separated to superna-
tants (S) and pellets (P) by centrifugation at 100,000 g for 1 h.
The distribution of Apg8 was examined by immunoblotting with
Apg8-specific antibodies.The Journal of Cell Biology, Volume 151, 2000 272
An Unidentified Molecule Is Conjugated to the 
Carboxy-terminal Gly Residue of Apg8FG
Anchorage of Apg8FG to membranes depended on its
carboxy-terminal Gly residue (Figs. 6 A and 7 A). Apg4
acted on Apg8FG* proteolytically (Fig. 7, B and C). Fur-
thermore, Apg4 was a protease that cleaved Apg8FGR
just after Gly116 (Fig. 4). These observations suggested
that Apg8FG might be attached to a component of mem-
brane via the carboxy-terminal Gly residue and the result-
ing conjugate (Apg8FG*) was cleaved by Apg4 just after
the Gly to regenerate Apg8FG.
We attempted to separate Apg8FGR, Apg8FG, and
Apg8FG* by standard SDS-PAGE. Apg8FGR and
Apg8FG (Apg8 generated from Apg8-myc by Apg4 in
vitro) had clearly different mobilities (Fig. 8 A, 1 and 2),
but Apg8FG* migrated close to them (data not shown). To
separate Apg8FG* from Apg8FGR and Apg8FG, we mod-
ified the procedure for SDS-PAGE by including 6 M urea
in the separating gel. As shown in Fig. 8 B (1, 2, and 4),
Apg8FG* (Apg8 in the LSP prepared from Dapg4Dapg8
cells that expressed Apg8FG) was then clearly distinguish-
able from Apg8FGR and Apg8FG, while Apg8FGR and
Apg8FG became indistinguishable. Using this method, we
were able to detect Apg8 in wild-type cells as doublet
bands of Apg8FG (Fig. 8 B, 6, top) and Apg8FG* (bot-
tom). In Dapg7 cells, newly synthesized Apg8 was com-
pletely cleaved by Apg4 (Fig. 1 B), but the cleaved Apg8
was not converted to the NaCl-insoluble form and was not
detected in the LSP. Thus, these defects should explain the
failure in the conversion of Apg8FG to Apg8FG*. Fig. 8, A
and B (2–4), clearly shows that Apg8 in Dapg7 cells existed
as Apg8FG and was not converted to Apg8FG*. Further-
more, the Apg8 released from the LSP prepared from
Dapg4Dapg8 cells that expressed Apg8FG had the same
mobility as Apg8FG. This result indicates that Apg8FG*
corresponds to Apg8FG conjugated with a small molecule
at its carboxy-terminal Gly residue.
Discussion
On the basis of our results, we propose a model for the se-
rial modification of Apg8 (Fig. 9). First, newly synthesized
Apg8 (Apg8FGR) is cleaved just after Gly116 by Apg4, a
novel cysteine protease, and is converted to Apg8 with a
Gly residue exposed at its carboxy terminus (Apg8FG).
Subsequently, by a ubiquitination-like mechanism,
Apg8FG is conjugated to an unidentified molecule “X”
via its carboxy-terminal Gly residue (see below). The re-
sulting conjugate, designated Apg8FG-X (Apg8FG*), is
tightly bound to membranes. Finally, the Apg8FG-X con-
jugate is cleaved by the proteolytic action of Apg4 and
Apg8FG is released from membranes or returned to
loosely membrane-bound. The liberated Apg8FG from X
are probably recycled and participate in a new conjugation
reaction. Alternatively, it might be entrapped in an au-
tophagosome or a Cvt vesicle, and then transported to a
vacuole, as described previously (Kirisako et al., 1999).
Apg4 efficiently cleaved Apg8FGR in logarithmically
growing cells (Figs. 1 and 3 B). The carboxy-terminal Arg
residue of Apg8FGR seems to have no physiological sig-
nificance because expression of Apg8FG overcame defects
Figure 8. Mobilities of Apg8FGR, Apg8FG. and Apg8FG* (A)
Standard SDS-PAGE. (1) Apg8 expressed in Dapg4 cells
(Apg8FGR), (2) Apg8 generated by cleavage of Apg8-myc in
vitro (Apg8FG; see Fig. 2 A), (3) Apg8 in Dapg7 cells (Apg8FG).
(B) SDS-PAGE in the presence of urea. Each sample was re-
solved in standard sample buffer for SDS-PAGE and subjected
to electrophoresis on a modified slab gel, with subsequent immu-
noblotting with Apg8-specific antibodies. The modified gel con-
sisted of a standard stacking gel and a 13.5% polyacrylamide sep-
arating gel that contained the standard concentration of SDS and
6 M urea. (1–3) The same samples as in A (1–3), (4) Apg8FG*
(Apg8 recovered in the LSP of Dapg4Dapg8 cells that expressed
Apg8FG), (5) Apg8 (Apg8FG) released from the LSP by cleav-
age in vitro by Apg4 (see Fig. 7 C), (6) Apg8 (Apg8FG and
Apg8FG*) in wild-type cells. *Apg8FGR, **Apg8FG,
***Apg8FG*.
Figure 9. Schematic model of
the serial modification of Apg8.
First, Apg8FGR (newly synthe-
sized Apg8) is converted to
Apg8FG as a result of pro-
teolytic cleavage by Apg4. The
intracellular site of this cleavage
remains to be determined. Sec-
ond, Apg8FG is converted to
Apg8FG-X via a reaction that
resembles ubiquitination and
becomes tightly membrane
bound. The molecule X might
be buried in a membrane. Fi-
nally, Apg8FG-X is reversed to
soluble or loosely membrane
bound Apg8FG by proteolytic
cleavage at the junction of
Apg8FG-X by Apg4. Some of
the reversed Apg8FG might be
recycled in a subsequent conju-
gation reaction.Kirisako et al. Reversible Modification of Apg8/Aut7 273
in both the autophagy and the Cvt pathway in Dapg8 cells
similarly to Apg8FGR (Fig. 5, B and C). This first cleavage
appears not to be a rate-limiting step in autophagy and in
the Cvt pathway, but it seems to be prerequisite for the
next modification of Apg8FG. The second modification is
essential for autophagy and the Cvt pathway, and the third
one is required for the normal progression of both path-
ways (Fig. 5). The reversible modification of Apg8FG that
determines its membrane-binding state might be tightly
linked both to autophagy and to the Cvt pathway.
Modification of Apg8FG Resembles Ubiquitination
During SDS-PAGE in the presence of urea, the mobility
of Apg8FG* was distinguishable from that of Apg8FG
and Apg8FGR and, furthermore, Apg8 generated from
Apg8FG* by the cleavage catalyzed by Apg4 was detected
at the same position as Apg8FG (Fig. 8 B). These observa-
tions indicate that Apg4 cleaves Apg8FG* just after
Gly116, as in the initial cleavage of Apg8FGR. Therefore,
some molecule must be attached to the carboxy-terminal
Gly residue of Apg8FG. This hypothesis is supported by
the fact that the carboxy-terminal Gly residue was essen-
tial for the conversion of Apg8FG to Apg8FG* (Fig. 6).
Ubiquitin and related molecules are conjugated to target
molecules via their carboxy-terminal Gly residue. In addi-
tion, ubiquitination and the conjugation of SUMO-1/Smt3
are accompanied by the deconjugation of the adducts
(Wilkinson, 1997; Li and Hochstrasser, 1999; Suzuki et al.,
1999). Thus, in some sense, the modification of Apg8FG
resembles ubiquitination and related conjugation reac-
tions. We postulated that a ubiquitination-like system
might participate in the modification of Apg8FG. As
shown in Figs. 6 and 8, Apg7 was necessary for the modifi-
cation of Apg8FG. Recently, we obtained direct evidence
that Apg7 functions as the E1 enzyme for Apg8FG
(Ichimura, Y., T. Kirisako, N. Ishihara, N. Mizushima, M.
Ohsumi, T. Noda, and Y. Ohsumi, manuscript in prepara-
tion). Furthermore, a molecule corresponding to the E2
enzyme for Apg8FG has also been identified (Ichimura,
Y., T. Kirisako, N. Ishihara, N. Mizushima, M. Ohsumi, T.
Noda, and Y. Ohsumi, manuscript in preparation). Thus, a
novel ubiquitination-like reaction seems certain to be in-
volved in the conversion of Apg8FG to Apg8FG* (hereaf-
ter referred to as Apg8FG-X).
Apg8FG and Apg8FG-X migrated similarly during
SDS-PAGE. Apg8FG-X was bound to membranes simi-
larly to integral membrane proteins in spite of the fact that
Apg8 has no membrane-spanning region (Figs. 6 and 7 B).
These observations suggest that the molecule X might be a
small molecule inserted in membranes. The target mole-
cules of ubiquitin and related molecules are proteins, so an
obvious candidate for X is a protein or peptide. However,
we know of no examples of a small protein or peptide
serving as an anchor in the membrane for a soluble pro-
tein. The target molecule of Apg8 might be another kind
molecule buried in membrane.
Sites at which the Reversible Modification of
Apg8 Occurs
In wild-type cells, the LSP contained Apg8FG-X exclu-
sively, whereas the HSP contained both Apg8FG and
Apg8FG-X (Fig. 6 B). The in vitro cleavage of Apg8FG-X
clearly showed that Apg8FG (generated from Apg8FG-X)
had less affinity to the membrane in the LSP, while it had
high affinity to the membrane in the HSP (Fig. 7 D). Thus,
at least two kinds of membranes to which Apg8 is bound
should exist in the cells.
On the basis of the fact described above and the data
that Apg8FG was recovered in the HSP without the con-
version to Apg8FG-X (Fig. 6 B), Apg8FG might undergo
conjugation to X on membrane structures recovered in the
HSP. X might be present either in the membrane at the
site of attachment of Apg8FG, or it might be recruited
from the other structures. Immunofluorescence micros-
copy revealed that Apg8 is localized on tiny dot structures
in the cytoplasm during vegetative growth (Kirisako et al.,
1999). It is possible that some of the dots represent
the sites at which Apg8FG is converted to Apg8FG-X. On
the other hand, the cleavage of Apg8FG-X occurs on the
membranes recovered in the HSP and in the LSP in vitro
(Fig. 7 D), but the primary site at which the cleavage pro-
ceeds in vivo remains to be elucidated. We reported previ-
ously that little Apg8 was detected on the membranes of
mature autophagosomes and autophagic bodies, while much
was detected on the membranes of premature autophago-
somes and their intermediate membrane structures (Kir-
isako et al., 1999). The deconjugation of Apg8FG-X may
occur on the premature autophagosomes (and possibly the
Cvt vesicles) and their intermediates.
Role of the Reversible Modification of Apg8 in 
Autophagy and the Cvt Pathway
Apg8 is required for the formation of autophagosomes and
the Cvt vesicles (Kirisako et al., 1999; Huang et al., 2000).
The conjugation of Apg8FG to X is crucial for autophagy
and the Cvt pathway. Thus, this conjugation reaction is es-
sential for the formation of autophagosomes and the Cvt
vesicles. We propose two possible roles for the modifica-
tion of Apg8FG in autophagy and the Cvt pathway.
One possible role for the modification is the production
of Apg8FG-X, which plays an essential role in the forma-
tion of autophagosomes and the Cvt vesicles. We pro-
posed previously that this process is accompanied by the
assembly of certain membrane structures to autophagoso-
mal membranes and involves the recruitment and the fu-
sion of membranes (Kirisako et al., 1999). In fact, it was
reported that fusion machinery is required before or at the
time of formation of the Cvt vesicles (Abeliovich et al.,
1999). A mammalian homologue of Apg8, GATE-16, was
reported to function in intra-Golgi transport at or near the
docking/fusion stage (Sagiv et al., 2000). Apg8, probably in
the form of Apg8FG-X, was found to be concentrated on
and around the intermediate membranes of autophago-
somes (Kirisako et al., 1999). Thus, Apg8FG-X might
function as a component of the membrane-docking and fu-
sion machinery. Alternatively, Apg8FG-X might function
during the budding of vesicles that are destined for the au-
tophagosomal membrane from certain source membrane
structures, just as ubiquitination is used during the inter-
nalization of plasma membrane proteins in the endocytic
pathway (Hicke and Riezman, 1996; Hicke, 1999).
It is also possible that the conjugation reaction itself
might play an essential role in vesicle formation. For ex-
ample, Apg8FG- and X-carrying structures might beThe Journal of Cell Biology, Volume 151, 2000 274
formed separately. The conjugation of Apg8FG to X
might serve to bind together the two kinds of structures
that are destined to participate in the formation of auto-
phagosomes or the Cvt vesicles. In addition, X will remain
in the membranes of the autophagosomes and the Cvt ves-
icles after the deconjugation of Apg8FG-X. Recruitment
of X might be crucial for the formation of autophago-
somes and the Cvt vesicles.
Loss of the ability to deconjugate of Apg8FG-X led to a
partial defect in autophagy and in the Cvt pathway (Fig. 5).
This defect is probably due to the accumulation of
Apg8FG-X on membranes as a result of loss of the second
proteolytic action of Apg4 (Fig. 6). Overproduction of
Apg8FG did not restore autophagic activity in Dapg4Dapg8
cells (data not shown). Therefore, a decrease in the level of
free Apg8FG cannot explain the defect. The accumulation
of Apg8FG-X might itself interfere with some steps in the
membrane dynamics in the two pathways.
Apg4 Is a Novel Cysteine Protease
Apg4 appears to be a novel cysteine protease that cleaves
both Apg8FGR and Apg8FG-X irrespective of the se-
quence downstream of Gly116. This property of Apg4 re-
sembles those of deubiquitinating enzymes (DUBs) and
the related enzyme that acts on SUMO-1/Smt3 conjugates
(Wilkinson, 1997; Li and Hochstrasser, 1999; Suzuki et al.,
1999). These are two families of DUBs: ubiquitin carboxy-
terminal hydrolases (UCHs) and ubiquitin-specific pro-
cessing proteases (UBPs). UCHs are generally proteins of
20–30 kD and their primary structures are well conserved.
By contrast, most UBPs are larger, 40–150 kD, and their
primary structures exhibit little homology, with the excep-
tion of some conserved regions that include Cys and His
boxes. Apg4 and its homologues have a well-conserved re-
gion that corresponds to the region from amino acids 154–
172 of Apg4) and includes the conserved cysteine residue,
which is probably part of the active site (Fig. 3 A). This re-
gion seems to correspond to the Cys box found in mem-
bers of the UBP family. In addition, alignment of the
amino acid sequences of Apg4 and its homologues re-
vealed another conserved region (corresponding to the re-
gion from residue 307 to 336 of Apg4) that includes one
conserved histidine residue. This region might be equiva-
lent to the His box of members of the UBP family. Apg4
and its homologues might form a fourth family of cysteine
proteases that deconjugates adducts via cleavage adjacent
to carboxy-terminal Gly residue. The first three families
are the UCH, UBP, and ULP (hydrolases for SUMO-1/
Smt3 conjugates) families. Deconjugation of ubiquitin and
Smt3 conjugates is required for a variety of cellular pro-
cesses, such as progression of the cell cycle and develop-
ment (Huang et al., 1995; Hegde et al., 1997; Wilkinson,
1997; Desterro et al., 1998; Li and Hochstrasser, 1999).
The requirement for deconjugation of Apg8FG-X in both
autophagy and the Cvt pathway also confirms the general
importance of this type of deconjugation reaction.
Apg4, Apg7, and Apg8 are well conserved from yeast to
higher eukaryotes. It is likely that the homologues of Apg8
undergo similar modifications, which play important roles
in autophagy, as Apg8. Furthermore, since there are at
least two homologues of Apg4 and several homologues of
Apg8 in mammals (Wang et al., 1999), it is possible that, in
higher eukaryotes, this kind of system is involved in a vari-
ety of intracellular processes. The precise role of Apg8 re-
mains to be elucidated, but there is no doubt that the re-
versible modification of Apg8FG is essential for change of
its membrane-binding state and is necessary for the non-
classical vesicular transport that is involved in autophagy
and the Cvt pathway. The unique membrane dynamics
that must operate formation of double membrane vesicles
might require a sophisticated set of reactions as demon-
strated by the present study.
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